414 related articles for article (PubMed ID: 19584161)
1. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.
Yip S; Miao J; Cahill DP; Iafrate AJ; Aldape K; Nutt CL; Louis DN
Clin Cancer Res; 2009 Jul; 15(14):4622-9. PubMed ID: 19584161
[TBL] [Abstract][Full Text] [Related]
2. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Cahill DP; Levine KK; Betensky RA; Codd PJ; Romany CA; Reavie LB; Batchelor TT; Futreal PA; Stratton MR; Curry WT; Iafrate AJ; Louis DN
Clin Cancer Res; 2007 Apr; 13(7):2038-45. PubMed ID: 17404084
[TBL] [Abstract][Full Text] [Related]
3. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
[TBL] [Abstract][Full Text] [Related]
4. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
Maxwell JA; Johnson SP; McLendon RE; Lister DW; Horne KS; Rasheed A; Quinn JA; Ali-Osman F; Friedman AH; Modrich PL; Bigner DD; Friedman HS
Clin Cancer Res; 2008 Aug; 14(15):4859-68. PubMed ID: 18676759
[TBL] [Abstract][Full Text] [Related]
5. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
Cahill DP; Codd PJ; Batchelor TT; Curry WT; Louis DN
Clin Neurosurg; 2008; 55():165-71. PubMed ID: 19248684
[No Abstract] [Full Text] [Related]
6. Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide.
McFaline-Figueroa JL; Braun CJ; Stanciu M; Nagel ZD; Mazzucato P; Sangaraju D; Cerniauskas E; Barford K; Vargas A; Chen Y; Tretyakova N; Lees JA; Hemann MT; White FM; Samson LD
Cancer Res; 2015 Aug; 75(15):3127-38. PubMed ID: 26025730
[TBL] [Abstract][Full Text] [Related]
7. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
Hunter C; Smith R; Cahill DP; Stephens P; Stevens C; Teague J; Greenman C; Edkins S; Bignell G; Davies H; O'Meara S; Parker A; Avis T; Barthorpe S; Brackenbury L; Buck G; Butler A; Clements J; Cole J; Dicks E; Forbes S; Gorton M; Gray K; Halliday K; Harrison R; Hills K; Hinton J; Jenkinson A; Jones D; Kosmidou V; Laman R; Lugg R; Menzies A; Perry J; Petty R; Raine K; Richardson D; Shepherd R; Small A; Solomon H; Tofts C; Varian J; West S; Widaa S; Yates A; Easton DF; Riggins G; Roy JE; Levine KK; Mueller W; Batchelor TT; Louis DN; Stratton MR; Futreal PA; Wooster R
Cancer Res; 2006 Apr; 66(8):3987-91. PubMed ID: 16618716
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma.
Sun Q; Pei C; Li Q; Dong T; Dong Y; Xing W; Zhou P; Gong Y; Zhen Z; Gao Y; Xiao Y; Su J; Ren H
Biochem Biophys Res Commun; 2018 Feb; 496(4):1040-1046. PubMed ID: 29366782
[TBL] [Abstract][Full Text] [Related]
9. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP
Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275
[TBL] [Abstract][Full Text] [Related]
10. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
[TBL] [Abstract][Full Text] [Related]
11. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
[TBL] [Abstract][Full Text] [Related]
12. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
13. MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature.
Gaspar N; Marshall L; Perryman L; Bax DA; Little SE; Viana-Pereira M; Sharp SY; Vassal G; Pearson AD; Reis RM; Hargrave D; Workman P; Jones C
Cancer Res; 2010 Nov; 70(22):9243-52. PubMed ID: 20935218
[TBL] [Abstract][Full Text] [Related]
14. The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
Johannessen TC; Prestegarden L; Grudic A; Hegi ME; Tysnes BB; Bjerkvig R
Neuro Oncol; 2013 Mar; 15(3):269-78. PubMed ID: 23258843
[TBL] [Abstract][Full Text] [Related]
15. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
Stritzelberger J; Distel L; Buslei R; Fietkau R; Putz F
Clin Transl Oncol; 2018 Apr; 20(4):508-516. PubMed ID: 28825189
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
[TBL] [Abstract][Full Text] [Related]
17. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.
Goellner EM; Grimme B; Brown AR; Lin YC; Wang XH; Sugrue KF; Mitchell L; Trivedi RN; Tang JB; Sobol RW
Cancer Res; 2011 Mar; 71(6):2308-17. PubMed ID: 21406402
[TBL] [Abstract][Full Text] [Related]
18. Germline MSH6 Mutation in a Patient With Two Independent Primary Glioblastomas.
Forsström LM; Sumi K; Mäkinen MJ; Oh JE; Herva R; Kleihues P; Ohgaki H; Aaltonen LA
J Neuropathol Exp Neurol; 2017 Oct; 76(10):848-853. PubMed ID: 28922847
[TBL] [Abstract][Full Text] [Related]
19. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
SongTao Q; Lei Y; Si G; YanQing D; HuiXia H; XueLin Z; LanXiao W; Fei Y
Cancer Sci; 2012 Feb; 103(2):269-73. PubMed ID: 22034964
[TBL] [Abstract][Full Text] [Related]
20. Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells.
Fabro F; Kers TV; Feller KJ; Beerens C; Ntafoulis I; Idbaih A; Verreault M; Connor K; Biswas A; Salvucci M; Prehn JHM; Byrne AT; O'Farrell AC; Lambrechts D; Dilcan G; Lodi F; Arijs I; Kremer A; Tching Chi Yen R; Chien MP; Lamfers MLM; Leenstra S
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
